GSK plc

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:01 2024-09-11 EDT			5-day change	1st Jan Change
1,654.50 ^GBX	-0.99%		-0.57%	+14.09%

09-11	GSK Reaches Another Settlement in Zantac Litigation	DJ
09-11	GSK plc Announces Change of Registered Office Address	CI

GSK : Goldman Sachs gives a Neutral rating

August 02, 2024 at 05:35 am

Analyst Rajan Sharma from Goldman Sachs research gives the stock a Neutral rating. The target price is unchanged and still at GBX 1850.

Latest news about GSK plc

GSK Reaches Another Settlement in Zantac Litigation	09-11	DJ
GSK plc Announces Change of Registered Office Address	09-11	CI
FTSE 100 in uninspiring gain before US data	09-11	AN
GSK's HPV Vaccine Misses Main Goal in Early-to-Mid Stage Study	09-11	MT
GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial	09-11	CI
GSK: shares fall back after disappointing clinical study	09-11	CF
GSK stresses need for innovation as herpes vaccine fails to progress	09-11	AN
GSK : Gets a Neutral rating from Goldman Sachs	09-11	ZD
GSK's Herpes Vaccine Candidate Fails to Meet Efficacy Goal in Early-stage Trial	09-11	MT
GSK Says Herpes Vaccine Candidate Study Failed to Meet Primary Objective	09-11	DJ
GSK : Goldman Sachs sticks Neutral	09-10	ZD
Live Co fails to reach agreement with creditor	09-09	AN
GSK Says Depemokimab Results Show 54% Decrease in Severe Asthma Exacerbations	09-09	MT
GSK : Gets a Buy rating from Deutsche Bank	09-09	ZD
European Equities Close Sharply Lower in Friday Trading; EU, Euro Area GDP Decelerate	09-06	MT
European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Index Set to End Week 3.7% Lower	09-06	MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Friday	09-06	MT
Sector Update: Health Care	09-06	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Ahead of Key Jobs Report	09-06	MT
GSK's Phase 3 Trial of Nucala to Treat COPD Meets Primary Endpoint; Shares Rise 1% Pre-Bell	09-06	MT
EXECUTIVE CHANGES: Invinity replaces CEO; Gulf Keystone chair dies	09-06	AN
GSK plc Announces Positive Results from Phase III Trial of Nucala (Mepolizumab) in COPD	09-06	CI
GSK hails positive results of Nucala clinical trials in lung disease	09-06	AN
GSK: positive phase III data in COPD	09-06	CF
GSK's Nucala Drug Cuts COPD Exacerbations in Late-stage Study	09-06	MT

GSK plc is a global biopharma company. The Companyâs segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.

Employees

70,212

Sector

Pharmaceuticals

Calendar

2024-09-18 - Bank of America Global Healthcare Conference

Related indices

STOXX Europe 600 Index (EUR) , FTSE 100

More about the company